Oral Weight-Loss Drug Developer Kallyope Exploring IPO bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
(Bloomberg) Kallyope Inc., a US biotech that’s developing oral weight loss drugs, is exploring an initial public offering, according to people familiar with the matter, as the company seeks to capitalize on the investor frenzy around treatments for obesity. Most Read from BloombergChina Weighs Stock Market Rescue Package Backed by $278 BillionApple Dials Back Car’s Self-Driving Features and Delays Launch to 2028Netflix Pays $5 Billion for ‘Raw’ in Bet on Live EventsAn Isolated Israel Doubles
By Gisela Sommer, Epoch Times | September 2, 2013 Last Updated: September 2, 2013 10:50 pm A screen shot from the mini documentary, "Killed for Organs: China's Secret State Transplant Business." The German newspaper Die Zeit points to Western complicity in the ongoing organ pillaging in China. (Courtesy of NTD Television) In China, one gets…
Appointment strengthens Company's global management team, brings vast capital market expertise, unique network in the global financial community, and robust operational industry experience Appointment
HMNC Brain Health Embarks on Next Phase of Growth with New Leadership Team
Dr. Hans Eriksson appointed Chief Clinical Development Officer
Dr. Franz Humer strengthens Board of Directors as Chairman
Founder Prof. Dr. Dr. Dr. h.c. mult. Florian Holsboer to lead Scientific Advisory Board
MUNICH, GERMANY / ACCESSWIRE / April 22, 2021 / HMNC Brain Health, a biotech company focused on the development of innovative and personalized treatments for depression and other neuropsychiatric disorders, enters a new phase of growth with a new leadership team. Benedikt von Braunmühl, formerly COO, Diagnostic Services of Medicover, will take over as Chief Executive Officer with effect of May 1, 2021. He will succeed the company founder Prof. Florian Holsboer who already stepped up to the Board of Directors and now also took over the lead of the Scientific Board. Dr. Hans Eriksson, most recently Chief Medical Officer at COMPASS Pathways, further strengthens the Executive Board as Chief Clinical Dev